Technology for efficient activation of NKT cells
US11744860B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 14, 2017 |
| Grant date | Sep 5, 2023 |
| Priority date | — |
| Expiry date | Oct 4, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-γ production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.